International Psoriasis Council
Sotyktu™(deucravacitinib), an oral treatment for adults with moderate to severe plaque psoriasis. Sotyktu™ is the only approved TYK2 inhibitor worldwide
Arcutis Biotherapeutics, Inc announced Arcutis Cares, a patient assistance program (PAP) for financially qualified uninsured and underinsured patients.
The Society of Investigative Dermatology (SID) Annual Meeting returned to an in-person format in 2022 for the first time in
Claro, a digital platform built to improve mental health for those with psoriasis who are living in Spain, the United
The Society of Investigative Dermatology (SID) Annual Meeting returned to an in-person format in 2022 for the first time in
Eli Lilly announced a new formula for Taltz® that contains the same active ingredient as the original formulation, but patients
ZORYVE is the first and only topical phosphodiesterase-4 (PDE4) inhibitor approved to treat plaque psoriasis. The product is expected to
Arcutis Biotherapeutics, Inc. shared their finding from the Skin Insights: Uncovering Psoriasis Survey.
Dermavant announced the FDA approval for VTAMA® (tapinarof) cream, 1% for the Treatment of Plaque Psoriasis in Adults. This is
Amgen presents new data on the efficacy of apremilast in patients with mild to moderate plaque psoriasis and in patients